Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. (2019)
Attributed to:
Epidemiological and statistical research on health problems of developing countries: MRC Tropical Epidemiology Group
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/infdis/jiz070
PubMed Identifier: 30796818
Publication URI: http://europepmc.org/abstract/MED/30796818
Type: Journal Article/Review
Volume: 220
Parent Publication: The Journal of infectious diseases
Issue: 1
ISSN: 0022-1899